Retrospective Study by Eli Lilly: Patient Outcomes & Costs Related to Muscle Atrophy & Weakness post Total Hip Replacement

Results of a retrospective study by United BioSource and Eli Lilly on 43 thousand total hip patients. The full study can be seen here: Link

Among US patients undergoing THA, those with MAW had higher health care resource use and costs as compared to those without MAW. Commercially insured patients with MAW were also more likely to have any all-cause, as well as replacement-related, subsequent hospitalization than those without MAW.